Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?
Expert Opinion on Pharmacotherapy, 2023•Taylor & Francis
ABSTRACT Introduction Female sexual dysfunctions (FSDs) are common in women of any
age and have a huge impact on quality of life and relationships. They have a multifaceted
etiology limiting the development of pharmacotherapies with a high rate of effectiveness.
Safety issues are also a concern. Areas covered The authors report the most recent
advances in pharmacotherapy for premenopausal and postmenopausal women with a main
focus on hypoactive sexual desire disorders (HSDD) and associated sexual symptoms …
age and have a huge impact on quality of life and relationships. They have a multifaceted
etiology limiting the development of pharmacotherapies with a high rate of effectiveness.
Safety issues are also a concern. Areas covered The authors report the most recent
advances in pharmacotherapy for premenopausal and postmenopausal women with a main
focus on hypoactive sexual desire disorders (HSDD) and associated sexual symptoms …
Introduction
Female sexual dysfunctions (FSDs) are common in women of any age and have a huge impact on quality of life and relationships. They have a multifaceted etiology limiting the development of pharmacotherapies with a high rate of effectiveness. Safety issues are also a concern.
Areas covered
The authors report the most recent advances in pharmacotherapy for premenopausal and postmenopausal women with a main focus on hypoactive sexual desire disorders (HSDD) and associated sexual symptoms. Good levels of evidence have emerged for psychoactive agents, such as flibanserin and bremelanotide, as well as hormonal compounds (transdermal testosterone). The authors also report briefly on intravaginal DHEA (prasterone), local estrogen therapy (LET), and ospemifene to manage effectively vulvovaginal atrophy/genitourinary syndrome of menopause (VVA/GSM). In addition, they discuss promising therapeutic options highlighting the main reasons that hamper the availability of new labeled products. Finally, they include the importance of the multimodal approach to address FSDs.
Expert opinion
Approved pharmacotherapies for FSD are limited. Validated multidimensional instruments and adequate objective measures of physical and mental responses to sexual external and internal incentives are mandatory to identify women suitable to chronic or on-demand treatments and to assess their pattern of response in research and practice.
![](/scholar/images/qa_favicons/tandfonline.com.png)
以上显示的是最相近的搜索结果。 查看全部搜索结果